RecruitingPhase 2NCT06650514

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

Studying Osteosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vall d'Hebron Institute of Oncology
Intervention
OMO-103(drug)
Enrollment
10 enrolled
Eligibility
12 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Collaborators

Peptomyc S.L. · Osteosarcoma Institute · Curing Kids' Cancer Foundation · Dana-Farber Cancer Institute · Memorial Sloan Kettering Cancer Center · Oregon Health and Science University · The Morgan Adams Foundation · The Kristen Ann Carr Fund

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06650514 on ClinicalTrials.gov

Other trials for Osteosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Osteosarcoma →

← Back to all trials